Literature DB >> 8793275

HMG-CoA reductase inhibitors: role in normal and malignant cells.

O Larsson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8793275     DOI： 10.1016/1040-8428(96)00193-x

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN： 1040-8428            Impact factor:   6.312


× No keyword cloud information.
  20 in total

1.  Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer.

Authors:  Vidyalakshmi Sethunath; Huizhong Hu; Carmine De Angelis; Jamunarani Veeraraghavan; Lanfang Qin; Nicholas Wang; Lukas M Simon; Tao Wang; Xiaoyong Fu; Agostina Nardone; Resel Pereira; Sarmistha Nanda; Obi L Griffith; Anna Tsimelzon; Chad Shaw; Gary C Chamness; Jorge S Reis-Filho; Britta Weigelt; Laura M Heiser; Susan G Hilsenbeck; Shixia Huang; Mothaffar F Rimawi; Joe W Gray; C Kent Osborne; Rachel Schiff
Journal:  Mol Cancer Res       Date:  2019-08-16       Impact factor: 5.852

2.  CAAX-box protein, prenylation process and carcinogenesis.

Authors:  Juehua Gao; Jie Liao; Guang-Yu Yang
Journal:  Am J Transl Res       Date:  2009-05-25       Impact factor: 4.060

3.  Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway.

Authors:  William A Freed-Pastor; Hideaki Mizuno; Xi Zhao; Anita Langerød; Sung-Hwan Moon; Ruth Rodriguez-Barrueco; Anthony Barsotti; Agustin Chicas; Wencheng Li; Alla Polotskaia; Mina J Bissell; Timothy F Osborne; Bin Tian; Scott W Lowe; Jose M Silva; Anne-Lise Børresen-Dale; Arnold J Levine; Jill Bargonetti; Carol Prives
Journal:  Cell       Date:  2012-01-20       Impact factor: 41.582

4.  p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression.

Authors:  Sung-Hwan Moon; Chun-Hao Huang; Shauna L Houlihan; Kausik Regunath; William A Freed-Pastor; John P Morris; Darjus F Tschaharganeh; Edward R Kastenhuber; Anthony M Barsotti; Rachel Culp-Hill; Wen Xue; Yu-Jui Ho; Timour Baslan; Xiang Li; Allison Mayle; Elisa de Stanchina; Lars Zender; David R Tong; Angelo D'Alessandro; Scott W Lowe; Carol Prives
Journal:  Cell       Date:  2018-12-20       Impact factor: 41.582

5.  Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer.

Authors:  Lu Zhang; Panayotis C Theodoropoulos; Ugur Eskiocak; Wentian Wang; Young-Ah Moon; Bruce Posner; Noelle S Williams; Woodring E Wright; Sang Bum Kim; Deepak Nijhawan; Jef K De Brabander; Jerry W Shay
Journal:  Sci Transl Med       Date:  2016-10-19       Impact factor: 17.956

6.  Statin-induced GGPP depletion blocks macropinocytosis and starves cells with oncogenic defects.

Authors:  Zhihua Jiao; Huaqing Cai; Yu Long; Orit Katarina Sirka; Veena Padmanaban; Andrew J Ewald; Peter N Devreotes
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-12       Impact factor: 11.205

7.  Dysregulation of the mevalonate pathway promotes transformation.

Authors:  James W Clendening; Aleks Pandyra; Paul C Boutros; Samah El Ghamrasni; Fereshteh Khosravi; Grace A Trentin; Anna Martirosyan; Anne Hakem; Razqallah Hakem; Igor Jurisica; Linda Z Penn
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-09       Impact factor: 11.205

Review 8.  Multitasking of the 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor: beyond cardiovascular diseases.

Authors:  Paolo Calabro; Edward T H Yeh
Journal:  Curr Atheroscler Rep       Date:  2004-01       Impact factor: 5.113

9.  Mevalonate pathway is a therapeutic target in esophageal squamous cell carcinoma.

Authors:  Jianxin Shi; Ji Zhu; Heng Zhao; Chenxi Zhong; Zhiyun Xu; Feng Yao
Journal:  Tumour Biol       Date:  2012-11-21

Review 10.  The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics.

Authors:  Pedro M R Cruz; Huanbiao Mo; Walter J McConathy; Nirupama Sabnis; Andras G Lacko
Journal:  Front Pharmacol       Date:  2013-09-25       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.